Investigational Therapies and Life-Cycle Managementicon

Looking to the future – our innovative investigational therapies

Conducted from Tillotts Pharma’s headquarters, our R&D activities primarily focus on the life-cycle management of our own products and the development of innovative new treatment concepts in the digestive field. We lead large Phase III studies on a global scale, demonstrating our commitment to the commercialisation of new products and providing more treatment options for those with GI-diseases.

In addition to our current product portfolio, Tillotts has the following ongoing programmes:

Product Indication Active ingredient Development phase Partner/innovator
TP01 / Colpermin™ Irritable bowel syndrome Peppermint oil Launched/registration N/A
TP02 / Asacol™ 800 mg Mild to moderate ulcerative colitis Mesalazine (5-ASA) Launched/registration N/A
TP08 Ulcerative proctitis Mesalazine (5-ASA) Formulation development N/A
TP09 Familial adenomatous polyposis Eflornithine/Sulindac Phase III Cancer Prevention Pharmaceuticals
TP10 Not disclosed Anti-TNF-alpha Pre-clinical Not disclosed
TP20b Crohn's Disease – Life Cycle Management Budesonide Formulation development N/A

PROGRAMME DESCRIPTIONS

Last update: July 2017.

All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, Octasa®, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep®, Entocort®, Entocir™, Entocord™ and Budecol™ and are either registered or applied for in up to 70 countries (transfer of registrations to Tillotts pending in certain countries). The rights to Asacol, including the rights to the trademark, are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg. The rights to Colpermin, including the rights to the trademark, are owned by Tillotts in various countries except for the following: United Kingdom and Ireland.

Product information on this website is limited, with the aim of providing a summary for general information purposes for a wide audience regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.